ATE432940T1 - Substituierte isochinolin-3-carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel - Google Patents

Substituierte isochinolin-3-carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel

Info

Publication number
ATE432940T1
ATE432940T1 AT05004047T AT05004047T ATE432940T1 AT E432940 T1 ATE432940 T1 AT E432940T1 AT 05004047 T AT05004047 T AT 05004047T AT 05004047 T AT05004047 T AT 05004047T AT E432940 T1 ATE432940 T1 AT E432940T1
Authority
AT
Austria
Prior art keywords
production
carbonic acid
acid amides
medicinal products
substituted isoquinoline
Prior art date
Application number
AT05004047T
Other languages
German (de)
English (en)
Inventor
Klaus Weidmann
Karl-Heinz Baringhaus
Georg Tschank
Ulrich Werner
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Application granted granted Critical
Publication of ATE432940T1 publication Critical patent/ATE432940T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AT05004047T 1997-10-20 1998-10-16 Substituierte isochinolin-3-carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel ATE432940T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19746287A DE19746287A1 (de) 1997-10-20 1997-10-20 Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
ATE432940T1 true ATE432940T1 (de) 2009-06-15

Family

ID=7846053

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05004047T ATE432940T1 (de) 1997-10-20 1998-10-16 Substituierte isochinolin-3-carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel
AT98119591T ATE299148T1 (de) 1997-10-20 1998-10-16 Substituierte isochinolin-3-carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT98119591T ATE299148T1 (de) 1997-10-20 1998-10-16 Substituierte isochinolin-3-carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel

Country Status (24)

Country Link
US (1) US6093730A (enExample)
EP (2) EP1538160B1 (enExample)
JP (2) JP3782591B2 (enExample)
KR (1) KR100618922B1 (enExample)
CN (1) CN1117079C (enExample)
AR (1) AR013696A1 (enExample)
AT (2) ATE432940T1 (enExample)
AU (1) AU755714B2 (enExample)
BR (1) BR9804504B1 (enExample)
CA (2) CA2250664A1 (enExample)
CZ (1) CZ337298A3 (enExample)
DE (3) DE19746287A1 (enExample)
DK (2) DK0911340T3 (enExample)
ES (2) ES2328156T3 (enExample)
HU (1) HUP9802422A3 (enExample)
ID (1) ID21115A (enExample)
IL (1) IL126638A0 (enExample)
NO (1) NO312365B1 (enExample)
NZ (1) NZ332363A (enExample)
PL (1) PL192354B1 (enExample)
PT (1) PT911340E (enExample)
SG (1) SG87776A1 (enExample)
TR (1) TR199802106A3 (enExample)
ZA (1) ZA989505B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001275014A1 (en) * 2000-05-30 2001-12-11 Neurogen Corporation Imidazoloisoquinolines
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
ES2414706T3 (es) * 2001-12-06 2013-07-22 Fibrogen, Inc. Métodos para aumentar la eritropoyetina endógena
EP2295060B1 (en) 2001-12-06 2018-10-31 Fibrogen, Inc. Treatment or prevention of ischemic or hypoxic conditions
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
WO2005007192A2 (en) * 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
WO2004108681A1 (en) * 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
EP1893186A2 (en) * 2005-06-06 2008-03-05 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
DE602006014843D1 (de) 2005-06-15 2010-07-22 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
US7728130B2 (en) 2005-12-09 2010-06-01 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
DK2044028T3 (da) 2006-01-27 2012-08-20 Fibrogen Inc Cyanoisoquinolinforbindelser til stabilisering af den hypoxiinducerende faktor (HIF)
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
US7625927B2 (en) 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
BRPI0710048A2 (pt) * 2006-03-30 2011-08-02 Lg Electronics Inc método e aparelho para decodificar / codificar um sinal de vìdeo
BRPI0710527B8 (pt) 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
BRPI0713350B1 (pt) 2006-06-26 2022-04-12 Akebia Therapeutics Inc Composto, e, composição
ES2393326T3 (es) 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
US7635715B2 (en) 2006-12-18 2009-12-22 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
CA2683956C (en) 2007-04-18 2012-12-18 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
WO2008130508A1 (en) 2007-04-18 2008-10-30 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
WO2008137060A1 (en) 2007-05-04 2008-11-13 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
AU2008248165B2 (en) 2007-05-04 2011-12-08 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
US8962530B2 (en) * 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
CN101497584B (zh) * 2008-01-29 2010-12-22 首都医科大学 异喹啉-3-甲酰氨基酸苄酯及其制备和应用
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
CN102272117B (zh) 2008-11-14 2015-06-17 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
TWI485150B (zh) * 2009-07-17 2015-05-21 Japan Tobacco Inc 三唑并吡啶化合物及其作為脯胺醯基羥化酶抑制劑或紅血球生成素生產誘導劑之作用
NO2686520T3 (enExample) 2011-06-06 2018-03-17
WO2013013609A1 (en) * 2011-07-22 2013-01-31 Zhejiang Beta Pharma Incorporation Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
EP2776023B1 (en) 2011-10-25 2016-03-09 Janssen Pharmaceutica, N.V. Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
SG11201405574UA (en) 2012-03-09 2014-10-30 Fibrogen Inc 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
CN109369524A (zh) 2012-07-16 2019-02-22 菲布罗根有限公司 脯氨酰羟化酶抑制剂的晶体形态
HUE034409T2 (en) * 2012-07-16 2018-02-28 Fibrogen Inc Process for the preparation of isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
WO2014070859A1 (en) * 2012-10-30 2014-05-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stat3 dimerization inhibitors
EP2951159B1 (en) 2013-01-24 2018-08-22 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
CN105377242A (zh) 2013-06-06 2016-03-02 菲布罗根有限公司 Hif羟化酶抑制剂的药物制剂
NZ714963A (en) 2013-06-13 2020-07-31 Akebia Therapeutics Inc Compositions and methods for treating anemia
TWI846166B (zh) 2013-11-15 2024-06-21 美商阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途
CN106535877A (zh) 2014-05-15 2017-03-22 英斯梅德股份有限公司 用于治疗肺部非结核性分枝杆菌感染的方法
JP2018502882A (ja) 2015-01-23 2018-02-01 アケビア セラピューティクス インコーポレイテッドAkebia Therapeutics Inc. 2−(5−(3−フルオロフェニル)−3−ヒドロキシピコリンアミド)酢酸の固体形態、その組成物及び使用
UA123308C2 (uk) 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії
EP4667059A2 (en) * 2015-05-28 2025-12-24 Japan Tobacco Inc. Method for treating or preventing diabetic nephropathy
JP6884714B2 (ja) * 2015-07-09 2021-06-09 インスメッド インコーポレイテッド 肺疾患及び肺損傷を治療するための組成物及び方法
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es) * 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
WO2019139956A2 (en) * 2018-01-09 2019-07-18 Cornell University Prevention and treatment of organ fibrosis
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
AU2019265629B2 (en) 2018-05-09 2024-09-12 Akebia Therapeutics, Inc. Process for preparing 2-((5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino)acetic acid
US20210299116A1 (en) * 2018-08-03 2021-09-30 Cornell University Methods for reducing abnormal scar formation
TWI865563B (zh) 2019-07-30 2024-12-11 德商拜耳動物保健有限公司 新穎異喹啉衍生物
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN112979541B (zh) * 2019-12-17 2022-11-11 浙江大学 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用
CN116120340B (zh) * 2021-11-15 2023-10-31 艾立康药业股份有限公司 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015255A1 (de) * 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
EP0548883A1 (de) * 1991-12-24 1993-06-30 Hoechst Aktiengesellschaft Substituierte Pyridin-N-oxide, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4233124A1 (de) * 1992-10-02 1994-04-07 Hoechst Ag Acylsulfonamido- und Sulfonamidopyridin-2-carbonsäureester sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2101420T3 (es) * 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
DK0650961T3 (da) * 1993-11-02 1997-09-15 Hoechst Ag Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler.
CA2138929A1 (en) * 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
IL135495A (en) * 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid

Also Published As

Publication number Publication date
ID21115A (id) 1999-04-22
HUP9802422A3 (en) 2002-02-28
PL329274A1 (en) 1999-04-26
DK1538160T3 (da) 2009-10-05
TR199802106A2 (xx) 1999-05-21
CN1117079C (zh) 2003-08-06
KR100618922B1 (ko) 2007-04-25
CA2251647A1 (en) 1999-04-20
CZ337298A3 (cs) 1999-05-12
JP3782591B2 (ja) 2006-06-07
NO984877L (no) 1999-04-21
ATE299148T1 (de) 2005-07-15
NO312365B1 (no) 2002-04-29
TR199802106A3 (tr) 1999-05-21
JPH11302257A (ja) 1999-11-02
HU9802422D0 (en) 1998-12-28
EP1538160A1 (de) 2005-06-08
DE19746287A1 (de) 1999-04-22
CA2251647C (en) 2011-08-30
ES2328156T3 (es) 2009-11-10
ES2245471T3 (es) 2006-01-01
EP0911340A2 (de) 1999-04-28
SG87776A1 (en) 2002-04-16
JP2006056894A (ja) 2006-03-02
HK1019605A1 (en) 2000-02-18
EP0911340B1 (de) 2005-07-06
IL126638A0 (en) 1999-08-17
EP1538160B1 (de) 2009-06-03
DK0911340T3 (da) 2005-11-07
BR9804504A (pt) 2001-05-22
NZ332363A (en) 2000-04-28
CN1218802A (zh) 1999-06-09
PT911340E (pt) 2005-09-30
DE59814365D1 (de) 2009-07-16
PL192354B1 (pl) 2006-10-31
CA2250664A1 (en) 1999-04-20
NO984877D0 (no) 1998-10-19
DE59812907D1 (de) 2005-08-11
EP0911340A3 (de) 1999-07-07
AU755714B2 (en) 2002-12-19
JP4691419B2 (ja) 2011-06-01
ZA989505B (en) 1999-04-20
AU8941398A (en) 1999-05-06
AR013696A1 (es) 2001-01-10
BR9804504B1 (pt) 2009-01-13
HUP9802422A2 (hu) 1999-08-30
US6093730A (en) 2000-07-25
KR19990037182A (ko) 1999-05-25

Similar Documents

Publication Publication Date Title
ATE432940T1 (de) Substituierte isochinolin-3-carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel
DE69817611D1 (de) 2-aryl-8-oxodihydropurin-derivate, ihre herstellung, ihre verwendung als medikamentenkomponente und deren intermediate
ATE239712T1 (de) Disubstituierte bicyclische heterocyclen, ihre herstellung und ihre verwendung als arzneimittel
ATE214371T1 (de) 3-hydroxy-pyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
ATE256680T1 (de) Pyrazol-derivate, ihre herstellung und ihre verwendung in arzneimitteln
DE59907961D1 (de) Indeno-, naphtho- und benzocyclohepta-dihydrothiazol derivate, deren herstellung und deren verwendung als anorektische arzneimittel
ATE299503T1 (de) Pyridin-3-carbonsäurederivate und ihre verwendung als zwischenprodukte
ATE522213T1 (de) Fünfgliedrige-heteroringderivate , ihre herstellung und ihre verwendung als arzneimittel
ATE302754T1 (de) Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69724142D1 (de) Sulfonamid-derivate, verfahren zur ihrer herstellung und ihre verwendung als arzneimittel
DE69916828D1 (de) Pyrazoline, ihre herstellung und verwendung als medikamente
DE69821623D1 (de) Derivate von acyl-piperazinil-pyrimidinen, ihre herstellung und verwendung als medikament
DE69814431D1 (de) 3,3-diarylpropylamine , ihre verwendung und herstellung
ATE243708T1 (de) Substituierte imidazolidinderivate, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
ATE217633T1 (de) Erythramicin-derivate, ihre verfahren zur herstellung und ihre verwendung als arzneimittel
DE59905572D1 (de) Substituierte 4-amino-2-aryl-pyrimidine, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
ATE222236T1 (de) Neue guanidinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE50003761D1 (de) Indeno-dihydrothiazol derivate, deren herstellung und deren verwendung als anorektische arzneimittel
DE59409541D1 (de) Bicyclen-derivate, ihre herstellung und verwendung
DE69521595D1 (de) Optisch-aktives Benzothiepin-Derivate, ihre Herstellung und Verwendung
DE59802922D1 (de) 3-substituierte tetrahydropyridopyrimidinon-derivate, ihre herstellung und verwendung
ATE268760T1 (de) Neue carbonsäurederivate, ihre herstellung und verwendung
ATE267811T1 (de) Substituierte 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin- 0-ole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69611303D1 (de) Benzolsulfonamidderivate, ihre herstellung und ihre therapeutische verwendung
DE60012750D1 (de) Neue xanthon derivate, deren herstellung und verwendung als arzneimittel